Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Metabolomics data are provided in the Supplementary Tables 3, 4
Key Clinical Implications First evidence linking GLP-1RA use to lower obesity-associated cancer incidence specifically in obese, nondiabetic patients Potential dual benefit for weight management and cancer risk reduction Racial disparities in treatment response warrant further investigation and may impact prescribing decisions Findings support existing trends toward expanded GLP-1RA use for obesity management beyond diabetes Bottom Line This large retrospective study provides the first evidence that GLP-1 receptor agonists may be associated with reduced cancer risk in obese adults without diabetes
Furthermore, blend formulations may provide a convenient format for investigators who wish to evaluate multiple peptide materials within a single research framework while maintaining consistency across study protocols
Take 1-2 capsules daily with food and water, or as directed by your healthcare provider
Membranes were probed with primary antibodies (all at 1:1,000 dilution) overnight at 4 C, and subsequently incubated with IRDye 800CW-conjugated goat anti-rabbit IgG or goat anti-mouse IgG (both at 1:10,000 dilution
US$ 29.33
US$ 23.91
US$ 27.32
US$ 23.30
US$ 28.41
